Vicus Therapeutics, LLC
Vicus Therapeutics, LLC (Vicus Therapeutics) is a privately held bio-pharmaceutical company engaged in the development of oncology supportive care therapies for the patients with cancer. The lead product of the company, VT-122, is an orally administered combination of propranolol, a non-selective beta adrenergic receptor blocker, and etodolac, a balanced COX1 and COX2 enzyme inhibitor, which helps in extension of life expectancy and improves quality-of-life and in cancer cachexia patients. Vicus Therapeutics operates in partnership with leading pharmaceutical companies in order to develop its drugs as components of multi-drug treatment regimens. The company is headquartered at Morristown, New Jersey, the US.